Use of FLT-TEP Scan as Predictive Marker and Early Prognostic in Patients Suffering From AML Treated by Chemotherapy
Positron emission tomography uses various radioactive tracers to measure the metabolic
activity in a none-invasive way, and specially to follow the activity of the disease during
Among those new tracers, fluorothymidine (18F-FLT) arouses a lot of interest. This new tool
would allow to image and follow time wise acute myeloid leukemia (AML). The investigators
want, with the (18F-FLT), to characterise the aggressivity of the tumours and the prognostic
before and after chemotherapy treatment.
The aim of this study is to be able to identify earlier the responders, because if they are
detected sooner, these patients will benefit from more aggressive treatments.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society